H.C. Wainwright analyst Swayampakula Ramakanth has maintained their bullish stance on XFOR stock, giving a Buy rating on March 25.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors that highlight X4 Pharmaceuticals’ potential for long-term growth. The company has shown significant progress in the commercialization of its drug Xolremdi, particularly for WHIM syndrome, with a notable increase in revenue in the fourth quarter of 2024. This growth is supported by strategic partnerships for the drug’s distribution in Europe, Australia, New Zealand, and the Middle East, which could expand its market reach significantly.
Additionally, X4 Pharmaceuticals is advancing its clinical trials for mavorixafor in treating chronic neutropenia, with promising developments in their Phase 3 study. The company’s financial health is also strong, with revenues exceeding expectations and a solid cash position that is projected to support operations into the first half of 2026. These factors collectively suggest a positive outlook for the company’s stock, justifying the Buy rating.
According to TipRanks, Ramakanth is an analyst with an average return of -0.4% and a 31.46% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Eton Pharmaceuticals, AbSci, and Vericel.
In another report released on March 25, Cantor Fitzgerald also maintained a Buy rating on the stock with a $3.00 price target.